Return to homepagePandemic Pact

COVID-19 therapeutics I: Drug combination for the therapeutic induction of T cells against COVID-19 (IndTCOVID-19) - compounds for clinical trials and peptides for immune monitoring

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:1 publications

Grant number: 16LW0004K

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $415,465.89

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Research Location

    Germany

  • Lead Research Institution

    EMC microcollections GmbH

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

1 Publication linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.